Analyzing C4 Therapeutics (NASDAQ:CCCC) & Celldex Therapeutics (NASDAQ:CLDX)

C4 Therapeutics (NASDAQ:CCCC) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk.

Analyst Ratings

This is a summary of current ratings and price targets for C4 Therapeutics and Celldex Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1	0	3	0	2.50
Celldex Therapeutics	1	1	11	0	2.77

C4 Therapeutics currently has a consensus target price of $8.50, suggesting a potential upside of 164.80%. Celldex Therapeutics has a consensus target price of $63.08, suggesting a potential upside of 109.23%. Given C4 Therapeutics’ higher probable upside, analysts clearly believe C4 Therapeutics is more favorable than Celldex Therapeutics.

Profitability

This table compares C4 Therapeutics and Celldex Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	N/A	N/A	N/A
Celldex Therapeutics	N/A	N/A	N/A

Institutional and Insider Ownership

78.8% of C4 Therapeutics shares are held by institutional investors. 5.6% of C4 Therapeutics shares are held by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares C4 Therapeutics and Celldex Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.04 million	11.27	-$123.03 million	($1.00)	-3.21
Celldex Therapeutics	N/A	N/A	N/A	($4.35)	-6.93

Celldex Therapeutics has lower revenue, but higher earnings than C4 Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

C4 Therapeutics beats Celldex Therapeutics on 5 of the 7 factors compared between the two stocks.

About C4 Therapeutics

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

About Celldex Therapeutics

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.